Xbrane Biopharma AB
F:7XB

Watchlist Manager
Xbrane Biopharma AB Logo
Xbrane Biopharma AB
F:7XB
Watchlist
Price: 1.037 EUR 10.26% Market Closed
Market Cap: 30.3m EUR

Intrinsic Value

The intrinsic value of one 7XB stock under the Base Case scenario is 11.332 EUR. Compared to the current market price of 1.037 EUR, Xbrane Biopharma AB is Undervalued by 91%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

7XB Intrinsic Value
11.332 EUR
Undervaluation 91%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Xbrane Biopharma AB

What is Valuation History?
Ask AI Assistant
What other research platforms think about 7XB?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is 7XB valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Xbrane Biopharma AB.

Explain Valuation
Compare 7XB to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about XBRANE?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Xbrane Biopharma AB

Current Assets 397.5m
Cash & Short-Term Investments 93.6m
Receivables 9.4m
Other Current Assets 294.5m
Non-Current Assets 304m
PP&E 86k
Intangibles 303.9m
Current Liabilities 114.4m
Accounts Payable 39.7m
Accrued Liabilities 73.4m
Other Current Liabilities 1.4m
Non-Current Liabilities -1k
Other Non-Current Liabilities -1k
Efficiency

Free Cash Flow Analysis
Xbrane Biopharma AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Xbrane Biopharma AB

Revenue
209.1m SEK
Cost of Revenue
-60.1m SEK
Gross Profit
149m SEK
Operating Expenses
-184.3m SEK
Operating Income
-35.3m SEK
Other Expenses
135.8m SEK
Net Income
100.5m SEK
Fundamental Scores

7XB Profitability Score
Profitability Due Diligence

Xbrane Biopharma AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
ROE is Increasing
Exceptional Net Margin
Exceptional Gross Margin
40/100
Profitability
Score

Xbrane Biopharma AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

7XB Solvency Score
Solvency Due Diligence

Xbrane Biopharma AB's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Low Altman Z-Score
64/100
Solvency
Score

Xbrane Biopharma AB's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

7XB Price Targets Summary
Xbrane Biopharma AB

Wall Street analysts forecast 7XB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 7XB is 5.645 EUR with a low forecast of 5.59 EUR and a high forecast of 5.812 EUR.

Lowest
Price Target
5.59 EUR
439% Upside
Average
Price Target
5.645 EUR
444% Upside
Highest
Price Target
5.812 EUR
460% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Xbrane Biopharma AB
does not pay dividends
Shareholder Yield

Current shareholder yield for XBRANE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one 7XB stock?

The intrinsic value of one 7XB stock under the Base Case scenario is 11.332 EUR.

Is 7XB stock undervalued or overvalued?

Compared to the current market price of 1.037 EUR, Xbrane Biopharma AB is Undervalued by 91%.

Back to Top